Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2016

Mar 3, 2016

30291_dirs_2016-03-03_26f9f9aa-9e45-471d-bd50-c1159c9aa279.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2015-02-12

Reporting Person: SCANGOS GEORGE A (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-02-12 Common Stock M 9189 Acquired 43466 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2015-02-12 Restricted Stock Unit $0 M 9189 Disposed 2017-02-12 Common Stock (9189) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 5378 Indirect
Common Stock 5378 Indirect

Footnotes

F1: This amendment is being filed to correct a typographical error. The number of shares vested was initially reported as 9,198 and should have been 9,189.

F2: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).